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Interaction between the sympathetic nervous system and renin-angiotensin system
in part relate to their common role in regulation of hemodynamics. Besides these
hemodynamic related interactions, some evidence was provided fbr direct receptor
mediated interactions behveen these systems. These direct interactions are possibly
involved in early compensated stages of heart Íàilure. In Part A the direct
interactions between the sympathetic nervous system and renin-angiotensin system
were further evaluated.
Chapter 2 presents the development and validation of a method that enables
study of these local interactions. This so called 'microdialysis' method is generally
accepted in experimental studies of the central nervous system. In this chapter
local norepinephrine release in the rat leti ventricle was monitored, in vivo,
without afÍ-ecting hemodynamics. Several experiments were pertbrmed to validate
whethetr the detected norepinephrine concentration was actually released from
sympathetic nerve endings. This, by means of locally applied type I or type II
reuptake inhibition using desipramine or cocaine respectively, inhibition of stress
induced catecholamine release by the voltage gated Na* channel blocker
tetrodotoxin, or monitoring of infused norepinephrine. The results show, that the
norepinephrine detected in these experiments was indeed released by sympathetic
nerve endings.
In chapter 3 the newly developed cardiac microdialysis method was employed
to further evaluate the direct interaction between the sympathetic nervous system
and renin-angiotemin system. This study shows that increasing doses of exogenous
angiotensin II stimulates endogenous norepinephrine release. Moreover, this
angiotensin Il-induced norepinephrine release was significantly reduced by local
administration of losartan. Consequently these experiments indicate that the renin-
angiotensin system is able to regulate sympathetic activation directly, involving
AT, receptors.
In PaÉ 81, the relative role of the sympathetic nervous system in heart failure
was snrdied by evaluating the eÍfècts of dopaminergic agonists. These compounds
were Íbund potentially usefull in the treatment of heart failure, since on the one
hand they are able to reduce the sympathetic drive, involving presynaptic Dr-like
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receptors, while on the other hand they are able to induces direct vasodilation,
involving postsynaptic D,-like receptors. However, although stimulation of
dopaminergic receptors may be Íàvourable in the treatment of heart Íailure, at
higher doses these compounds often also activate non-dopaminergic receptors,
such as a- and p-adrenoceptors. Stimulation of these receptors has known adverse
eÍÍ'ects. Since heart Íàilure may be accompanied by accumulation of drugs, this
non-dopaminergic receptor proÍile may be of particular importance Íbr the total
etfect of treatment with dopaminergic agonists.
ln chapter 4 the effècts of several dopaminergic agonists on human artery rings
were studied, rn vitro. This, to illustrate the potential Íavourable- and unÍavourable
eÍfècts of these compounds. The data show that these dopaminergic agonists
induce direct dilatation, when other interacting receptors are blocked. However,
when these interacting receptors were not blocked, ibopamine and dopamine
induced contraction, whereas 21046 did not. This contraction of ibopamine and
dopamine was mediated by a,-adrenoreceptor stimulation. The data show that, in
contrast to ibopamine and dopamine, 21046 inhibited a,-adrenoreceptor. In
conclusion, the study shows that the selectivity of these compounds should be
further improved, betbre use in treatment of heart lailure. Since it may be diÍlicult
to reach absolute selectivity Íbr dopaminergic receptors, the total receptor prolile
of these compounds is of particular importance. In this respect 21016 may be
usefull, although the eÍ1èct of this compound should be thoroughly tested,
particularly under diÍï'erent physiological conditions betbre use in heart Íàilure
patients.
Chapter 5 evaluates the ef'tects of relative selective doparninergic rcccptor
stimulation on ventricular remodeling atter experimental myocardial inÍarction in
rats. In l ine with the previous chapter, this study addresses the issue of whether
the receptor proÍiles of ibopamine ard 21046 are apropriate to treat heart Íailure.
Although there were no large diÍterences between treatment with ibopamine and
21046, there was a tendency to a further reduction of remodeling, and a
preservation of cardiac Í'unction aÍier treatment with 21046. Therefbre, these data
further establish the potential beneÍlcial eÍïècts of 21046. Untbrtunately, however,
further development of this compound was stopped, since the intrest in the
dopminergic concept declined aÍier the Íinding that mortality in heart tailure
patients increased aÍier ibopamine treatment.
In Part 82, the relative role of the renin-angiotensin systcrn in progression of
heart tailure was evaluated by comparing the eÍÍects of difl'erent intervcntion
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system was activated. As a result, of this local activation, these transgenic ratsdevelop fulminant hypertension, and thereby eventually lead to deveropment ofheart failure.
chapter 6 describes the protective eÍïects of diffèrent intervention strategies
on cardiovascular end-organ damage. In order to do so, a comparison was madebetween treatment with the angiotensin converting crzyme (ACE) inhibitor,quinapril, the angiotensin II AT, receptor antagonist, losartan, the mixed
a/B-antagonist, carvedilol, and the nonselective vasodilator, hydralazine. Losartan
and quinapril fully normalised blood pressure and prevented end-organ damage.In contrast, carvedilol and hydralazine did not prevent end-organ damage, despite
reduction of blood pressure. However, in these rater treatment groups bloodpressure was not fully normalised. ThereÍbre, we concluded 'rat end_organdamage dissociates Íiom blood pressure reduction when the ratter is not fully
normalised. Furthermore, no important diff'erences were fbund between treatment
with losartan or quinapril. Accordingly this, suggests that the end-organ damagein this model was primarily related to increased angiotensin II concentrations. Thedata do not exclude possible involvement of other pathways that are regulated by
angiotensin iI, such as the sympathetic nervous system. It is concruded thattreatment of hypertension should not be fbcussed merely on reduction of bloodpressure, but also on the underlying mechanism responsible Íbr this phenomenon.
chapter 7 evaluates the effects of treatment with quinapril, Iosartan andhydralazine on cardiac hypertrophy and B-adrenergic neuroeffèctor mechanisms
again in these hypertensive REN-2 rats. The study shows that part of the effects
of quinapril and losartan are mediated by preventrng deterioration of the
sympathetic innervation, since these compounds prevent a reduction of myocardial
norepinephrine content, as measured indirectly by determining co-transmitted
neuropeptide-Y concentrations. Furthermore, desensitization of the Badrenoceptor-G-protein-adenylyl cyclase complex was prevented by treatment withbot quinpril and losartan. Since treatment with losartan and quinaprit was equaily
eÍÏèctive, it was concluded that there were no important additional eÍfects ofbradykinin accunulation, prostaglandin production or alternative Í.ormation of
angiotensin IL Furthermore, the limited etlèct of hydralazine treatment was reratedboth to the moderate hemodynamic eÍ1ècts, and to the limited neuroendocrine
inhibitory properties.
In Part C, the possible synergistic eÍïects of combinecl inhibition of both rhe
sympathetic nervous system and renin-angiotensin system were studied. rn orderto do so, the neurohormonal consequences of B-blocker treatment as adjunt to
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ACE-inhibition were evaluated. Rational for this study lies in the fact that recent
clinical tials reported significant reduction in mortality after B-blockade against
placebo, in patients that were almost all treated with ACE-inhibitors. The
explanation tbr these beneÍlcial eÍtècts were Íbcussed primarily on improved
hemodynamic and not neurohormonal consequences of adjunctive B-blockade.
In chapter 8 these neurohormonal eÍl-ects of B-blockers in patients with
advanced heart Íàilure were studied. In order to do so, we compared the
neurohormonal profiles of patients treated without B-blockers or ACE-inhibitors,
and patients treated with ACE-inhibitors either with or without adjunctive p-
blocker treatment. We found that plasma renin-concentrations were signihcantly
higher after AcE-inhibition when compared to patients not on ACE-inhibition. In
contrast, plasma renine levels were not increased after combined p-blockade and
ACE-inhibit ion. The Íact that plasma renin levels were low despite chronic B-
blockade (in this study fbr an average period of 3.8 years), suggest that renine
release was not accompanied by Íbrmation of alternative routes of release.
Although actual angiotensin II concentrations were not measured in this study, it
is tempting to speculate that reduced renine release may be accompanied by lower
angiotensin lI concentrations. This, since renin is one of the rate limiting steps of
the renin-angiotensin cascade. This hypothesis was supported by the plasma
aldosterone and endothelin I concentrations, since these neurohormones that are
regulated in part by angiotensin II show tendency to further reduction aÍter
adjunctive B-blocker treatrnent when compared to patients only on ACE-inhibitors.
Further study of actual angiotensin II concentration is needed to establish the
theory.
In conclusion: The present thesis supports the concept that inhibition of the
sympathetic nervous system and the renin-angiotensin systcm is important in
reducing both development and progression of heart Íailure. Although inhibition
of either pathway was effèctive in treating heart failure, inhibtion of both pathways
was even more eÍïectve. The benef-icial eÍ-fects of combined treatment may result
from direct interactions between these pathways. As a consequence, combined
inhibition may be more efïective in restoration of the disturbed neurohormal
balance. However, extensive research aÍïer all phyiological and clinical
consequences of the interactions between these pathways is needed to confirm this
hypothesis.
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